18266

Atopic Dermatitis (Adolescent) – Research Trial – (62 Weeks)


Age: 6 Months



Participating Locations

No Clinics Found

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: July 16, 2024

Official Title

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID

NCT05735483

Sponsor

Eli Lilly and Company

Study Description

  • Brief Summary:

    The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis

  • Condition or Disease:

    Atopic Dermatitis,Eczema

  • Intervention/Treatment:

    Drug: Lebrikizumab,Drug: Placebo
  • Phase:

    PHASE3

  • Ages Eligible for Study:

    6 Months and 18 Years (CHILD,ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content